1 / 1

Ramucirumab(Cyramza)

Acetylcysteine Injection, FLUIMUCIL, Acetylcysteine InjectionAcetylcysteine Injection, FLUIMUCIL, Acetylcysteine InjectionAcetylcysteine Injection, FLUIMUCIL, Acetylcysteine Injection

Reference price:

Manufacturer:

Formulation:

INJECTION

Validity period:

Not specified in the specification.

Reminder: The outer packaging is for reference only, please purchase and use under the guidance of a pharmacist. For read by medical and pharmaceutical professionals only.

CYRAMZA (ramucirumab) is a fully human monoclonal antibody that functions as a vascular endothelial growth factor receptor 2 (VEGFR2) antagonist. By selectively binding to VEGFR2, CYRAMZA inhibits ligand-induced receptor activation, thereby blocking angiogenesis, a critical process in tumor growth and metastasis. This targeted mechanism underpins its clinical utility across multiple solid tumor types.

Approved for intravenous administration, CYRAMZA is utilized either as monotherapy or in combination with established chemotherapeutic regimens, depending on the cancer type and line of therapy. Its clinical application is supported by robust evidence from multiple phase III trials, demonstrating efficacy in improving outcomes for patients with advanced gastric, lung, colorectal, and liver cancers. The safety profile and dosing recommendations are tailored to each indication, with careful monitoring for specific adverse events such as hypertension, proteinuria, and hemorrhagic complications.

Generic name

Ramucirumab(Cyramza)

English name

Ramucirumab

Alternative Names

Cyramza

Drug prices

Indications

Advanced or metastatic gastric or gastro-esophageal junction (GEJ) adenocarcinoma, as monotherapy or with paclitaxel, after progression on or after fluoropyrimidine- or platinum-based chemotherapy.

Metastatic non-small cell lung cancer (NSCLC):

In combination with erlotinib for first-line treatment in patients with EGFR exon 19 deletions or exon 21 (L858R) mutations.

In combination with docetaxel for patients with disease progression on or after platinum-based chemotherapy (after progression on EGFR/ALK-targeted therapy if applicable).

Metastatic colorectal cancer (mCRC), in combination with FOLFIRI, after progression on or after bevacizumab, oxaliplatin, and a fluoropyrimidine.

Hepatocellular carcinoma (HCC), as monotherapy, in patients with alpha fetoprotein (AFP) ≥ 400 ng/mL who have been treated with sorafenib.

Therapeutic Target

Vascular endothelial growth factor receptor 2 (VEGFR2).

Active Ingredients

Ramucirumab (a fully human monoclonal antibody).

Dosage form

INJECTION

specifications

Single-dose vials containing either 100 mg/10 mL or 500 mg/50 mL solution.

Description

Ramucirumab is a recombinant human IgG1 monoclonal antibody that specifically binds to VEGFR2, inhibiting ligand-induced receptor activation and angiogenesis. The solution is clear to slightly opalescent, colorless to slightly yellow.

Dosage and Administration

For intravenous infusion only; do not administer as IV push or bolus.

Premedicate with a histamine-1 receptor antagonist before each infusion.

Gastric cancer: 8 mg/kg every 2 weeks, over 60 minutes (subsequent infusions may be over 30 minutes if tolerated).

NSCLC: 10 mg/kg every 2 weeks with erlotinib, or 10 mg/kg on day 1 of a 21-day cycle with docetaxel.

Colorectal cancer: 8 mg/kg every 2 weeks prior to FOLFIRI.

HCC: 8 mg/kg every 2 weeks.

Dose modifications for adverse reactions are specified (see Table 1 in the specification).

Dilute only with 0.9% sodium chloride to a final volume of 250 mL; do not use dextrose-containing solutions.

CATEGORY NAVIGATION